4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposiumâ„¢